Analyst: It could give Lundbeck a boost
New data on a Parkinsons drug that earned its developer, Lundbeck, more than a billion kroner last year could give the Danish company a fresh boost, says Alm. Brand analyst Michael Friis Jørgensen.
by Stefan Singh Kailay
Recently published data from a new study of Lundbeck and Teva’s Azilect could help boost sales of the Parkinson’s drug, says analyst Michael Friis Jørgensen from Alm. Brand Markets.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
